Topotecan

From OncoWiki
Jump to: navigation, search

Indication

Cervical Cancer

Chemotherapy for stage IVB (metastatic) cancer

  • Topotecan (Hycamtin) 1.5 mg/m2/d iv d1-5
  • Q3-4w

References

Muderspach, LI et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001; 81:213

Bookman, MA et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77:446

Endometrial Cancer

Chemotherapy for stage IVB (metastatic) cancer

  • Topotecan (Hycamtin) 1.2-1.5 mg/m2/d iv d1-5
  • Q3w

References

Wadler, S et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Study E3E93. J Clin Oncol 2003; 21:2110

Ovarian Epithelial Cancer

Chemotherapy for recurrent or metastatic cancer

Regimen 1

  • Topotecan (Hycamtin) 1-1.5 mg/m2/d iv over 30 min d1-5
  • Q3w
References

Gronlund, B et al. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 2002; 95:1656

Bookman, MA et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16:3345

Regimen 2

  • Topotecan (Hycamtin) 2.3 mg/m2/d po d1-5
  • Q3w
References

Clarke-Pearson, DL et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001; 19:3967

Lung Cancer Non Small Cell

Chemotherapy for stage IV (metastatic) cancer

  • Topotecan (Hycamtin) 1.5 mg/m2/d iv d1-5 q3w
References

Perez-Soler R et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14: 503

Lung Cancer Small Cell

Extensive stage

Regimen 1

  • Topotecan (Hycamtin) 2.3 mg/m2/d po d1-5 q3w
References

Eckardt JR et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25:2086

O'Brien M et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24:5441

Regimen 2

  • Topotecan (Hycamtin) 1.5 mg/m2/d iv over 30 minutes d1-5 q3w
References

Eckardt JR et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25:2086

Ardizzoni A et al. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090